StockPulse is a software subscription service that translates and summarizes U.S. stock filings and news into alerts. It is not an investment advisory, brokerage, or discretionary management service.

All information provided (filing summaries, price data, keywords, etc.) is processed from public sources for reference only and is not a recommendation to buy or sell any security. Investment decisions and their outcomes are the sole responsibility of the user.

노마드랩 주식회사 · 대표 황승준 · 사업자등록번호 588-81-01342

부산광역시 해운대구 센텀중앙로 55, 9층 7호(우동)

통신판매업 제2026-부산해운대-0983호 · 문의  

고객문의 070-4268-1176

App Store▶ Google Play
GuideFAQWeeklyTerms of ServicePrivacy PolicyPayment & Refund Policy

StockPulse · 스탁펄스(스톡펄스) — 미국주식 공시·뉴스 실시간 알림

© 2026 노마드랩 주식회사. All rights reserved.

StockPulseStockPulseFeedReportMacro·SectorsCommunityAlertsMy
Theme
FeedReportMacro·SectorsCommunityAlertsMy
OBXObsidian Therapeutics, Inc.
stockpulse.co.kr
Nasdaq
$13.98▲ 0.22%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
At a glance🔒 At-a-glance is MAX onlySee plans

Chart

Filings & news by date

Hover (PC) or tap (mobile) a candle to see that day only

🔒 Members only
Live tape🔒 Live tape is MAX onlySee plans

Filings

7
  • 10.5After-hours26.10.06 05:01
    SCHEDULE 13GOwnership#●●●

    Obsidian Therapeutics, Inc.

    Three entities, including Paradigm BioCapital Advisors LP, have filed a Schedule 13G regarding their beneficial ownership of Obsidian Therapeutics, Inc. common shares. This filing is made in accordance with a joint filing agreement dated October 5, 2026.…more

    $13.98+0.22%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    View filingShare
  • 9.10Regular26.09.11 00:05
    EFFECTOther

    Obsidian Therapeutics, Inc.

    Obsidian Therapeutics, Inc.'s registration statement (File No. 333-298642) became effective with the SEC on September 9, 2026. This effectiveness allows the company to proceed with the issuance and sale of the securities described in the filing.…more

    $13.98+0.22%vs prev close
    View filingShare
  • 8.28After-hours26.08.29 06:11
    S-1Offering

    Obsidian Therapeutics, Inc.

    Obsidian Therapeutics has filed an S-1 registration statement with the SEC for the resale of 29,164,045 shares of common stock held by existing selling stockholders. These shares were acquired through private placements and are being registered for potential sale, with an aggregate offering value of $517,944,689.99 based on a price of $17.7597 per share.…more

    $13.98+0.22%vs prev close
    View filingShare

6 more filings

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →

News

GlobeNewswire
  • 10.2Pre-market26.10.02 22:09
    #●●●#●●●

    Obsidian Therapeutics to Present Updated Clinical Data on OBX-115 at SITC 2026…more

    Obsidian Therapeutics will present updated safety and efficacy data from its Phase 1/2 Agni-01 study of OBX-115 in patients with immune-checkpoint inhibitor-resistant melanoma at the SITC 2026 meeting. The presentation will also highlight the progress of the trial's Phase 2 registration-enabling cohort.…more

    $13.98+0.22%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    ShareBenzinga
  • 8.28After-hours26.08.29 06:14

    ●●●●●●●● ●●●●● ●●●●●●

    Obsidian Therapeutics has filed a prospectus to facilitate the potential resale of up to 29.16 million shares by existing stockholders. This filing indicates a potential increase in circulating supply, which may exert downward pressure on the stock price due to dilution concerns.…more

    $13.98+0.22%vs prev close
    ShareBenzinga

1 more news items

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →